KN046 in Subjects With Advanced Solid Tumors and Lymphoma
This is a phase Ia/Ib, open-label, multicenter, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of KN046 in subjects with advanced solid tumors and lymphoma .
Advanced Solid Tumors|Lymphoma
DRUG: KN046
In the dose escalation part, number of participants with dose limiting toxicity (DLT)., During the first 4 weeks of treatment.|In the dose expansion part,Objective response rate (ORR)., Objective response is defined as complete response (CR) or partial response (PR), up to 2 years.|In the dose expansion part, Duration of response (DoR)., Duration of response is defined as the time period from the date of initial independent review committee assessed CR or PR until the date of PD or death from any cause, whichever occurs first., up to 2 years.
This is a phase Ia/Ib, open-label, multicenter, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of KN046 in subjects with advanced solid tumors and lymphoma .